Aseptic processing of a lobeline hydrochloride injection at 1.0 mg/mL lobeline base equivalent starts with dissolution of the API in Water for Injection at 20–25°C in a 316L stainless steel stirred vessel. The vehicle is adjusted with 0.9% w/v sodium chloride to an osmolality of 280–310 mOsm/kg and with 0.1 M hydrochloric acid or sodium hydroxide to pH 4.5–5.0 before sterile filtration. A 0.22 µm polyvinylidene fluoride membrane is preferred over nylon because the protonated alkaloid can exhibit adsorptive loss on unmodified nylon. Terminal steam sterilization at 121°C for 15 minutes should be supported by thermal challenge data; if assay loss exceeds 2.0% under this cycle, the vial-filling step is moved into a restricted access barrier system using aseptic filtration as the sole sterilization mechanism. Filling is performed on a peristaltic pump with a fill tolerance of ±3% into amber Type I glass vials sealed with bromobutyl rubber stoppers. The finished injection is tested for particulate matter per USP <788>, bacterial endotoxins per USP <85>, sterility per USP <71>, and osmolality per USP <785>. The principal operational boundary is pH: free lobeline base precipitates above pH 6.5, and the resulting turbidity is not reversible by simple agitation. In-line nitrogen or argon sparging at 0.5–1.0 L/min is applied when oxygen-sensitive degradation products are observed during forced degradation studies.

Why Does Direct-Compression Lobeline HCl Tablets Require Ordered Mixing Rather Than Simple Blending?

Lobeline hydrochloride is a low-dose alkaloid salt with a mean particle size commonly below 60 µm, whereas direct-compression lactose monohydrate has a D50 near 100–150 µm. This size mismatch produces segregation during bin transfer and tableting unless the API is first locked onto a carrier by ordered mixing. In a 1,000 L bin blender, the API is premixed with lactose monohydrate at 1:10 w/w for 10 minutes at 15 rpm, then diluted to 1:100 and mixed for an additional 20 minutes. The final blend contains lobeline HCl equivalent to 0.2–2.0 mg per tablet, microcrystalline cellulose at 45–65% w/w, crospovidone at 2–5% w/w, colloidal silicon dioxide at 0.5% w/w, and magnesium stearate at 0.5–1.0% w/w. Magnesium stearate is added last and blended for only 3–5 minutes because overlubrication lowers tablet tensile strength and delays disintegration. Tablets are compressed on a rotary tablet press with 9 mm round concave tooling at 8–14 kN compression force to a hardness of 5–8 kP, a thickness of 3.0–3.5 mm, and a friability below 1.0% per USP <1216>. Content uniformity follows USP <905>; an acceptance value above 15 has been associated on production-scale batches with powder layering on hopper walls, and the corrective action is a larger carrier-to-API surface coverage rather than extended total blend time. Disintegration is measured in purified water at 37±2°C and must not exceed 15 minutes per USP <701>. The finished tablets are packaged in 0.03 mm PVC/PVDC-aluminum blisters to limit moisture uptake because lobeline salts are hygroscopic above 60% RH.

For capsule-based dosing in equine practice, the veterinary compounding pharmacy usually prepares lobeline hydrochloride powders in size 2 or 3 two-piece hard gelatin capsules. The powder fill is lactose monohydrate 80M combined with the pre-weighed API in a geometric dilution sequence of 1:1, then 1:2, then 1:4 using a mortar and pestle for quantities below 100 g or a 5 L V-blender at 25 rpm for larger batches. The target fill weight is 150–250 mg per capsule, with the lobeline content adjusted to the prescribed dose rather than fixed per unit mass. Encapsulation is performed on a semi-automatic capsule machine with vibration-assisted dosing plates; weight variation is controlled within ±5% of the target fill weight. Because the formulation is non-sterile and dry, the beyond-use date assigned under USP <795> is generally 180 days when protected from moisture and light. The terminal product is a hard gelatin capsule placed in an amber screw-cap vial with desiccant silica gel canister; storage above 60% RH risks capsule shell embrittlement and API caking. For food-producing horses, compliance with 21 CFR 530.41 is evaluated before dispensing because extra-label use in feed animals carries residue and withdrawal considerations. Published efficacy data for this specific configuration is limited, and the capsule format is compounded only when a veterinarian determines that a solid oral dosage form is clinically appropriate.

Oral Vehicle pH Control for Neonatal Livestock Liquids

Water solubility of lobeline hydrochloride allows a pump-ready oral solution to be prepared, but the free base precipitates when phosphate or carbonate buffer systems raise pH above 6.0. An oral solution for neonatal piglets and calves is therefore manufactured with a citrate buffer at pH 4.5–5.0 and a total drug concentration of 0.5–1.0 mg/mL lobeline base equivalent. Glycerin or sorbitol solution 70% is included at 10–20% w/v to increase viscosity to 8–15 mPa·s, which reduces settling in the final 100 mL amber polyethylene terephthalate bottle. Preservative efficacy is maintained with sodium benzoate 0.1% w/v and potassium sorbate 0.1% w/v; both are added to purified water at 50°C and cooled to 25°C before the API is dissolved under propeller agitation at 500 rpm. The solution is passed through a 10 µm polypropylene filter to remove undissolved components and filled with a headspace nitrogen flush of 2–3 seconds. Light exposure promotes degradation, so the bottle label must specify storage at 20–25°C and protection from direct sunlight. The terminal product is a clear, slightly viscous oral solution with pH measured by USP <791>, viscosity by USP <911>, and deliverable volume per USP <698>. Incompatible conditions include contact with alkaline cleaning residues on filling lines; a final rinse with purified water at pH 5.0–5.5 is therefore required before startup. If the target species is a food-producing animal, residue data and withdrawal intervals must be established before administration because regulatory approval for this indication is not uniform across jurisdictions.

Fluid-Bed Wet Granulation of Lobeline Sulfate and Lactose Monohydrate

Granules are manufactured when veterinary hospitals require a pre-weighed oral unit that can be dispersed in water or administered by gavage. A wet granulation process binds lobeline sulfate API with lactose monohydrate 200M using povidone K-30 dissolved in purified water at 5% w/w of dry granulate. The API is first dispersed in a 1:5 pre-blend with lactose in a 150 L high-shear mixer at 100 rpm chopper speed for 3 minutes. The binder solution is sprayed at 8–12 g/min in a fluid-bed granulator with inlet air temperature 50–55°C, product temperature 35–40°C, and airflow 80–120 m³/h. Drying continues until loss on drying is below 2.0% w/w; overdrying below 0.5% w/w increases friable fines and segregation. The dried granules are milled through a 1,000 µm screen and blended with 0.25% w/w colloidal silicon dioxide in a 100 L bin blender. The resulting granules have bulk density 0.45–0.60 g/mL, tapped density 0.55–0.75 g/mL, and Carr compressibility index below 20% per USP <616>. Uniformity of dosage units on the filled granules follows USP <905>, with acceptance value not exceeding 15. The terminal product is an amber high-density polyethylene container with a heat-sealed foil liner, stored at 20–25°C and desiccant-protected. Granule production is preferred over dry blending when the API content is below 0.5% w/w because direct blend homogeneity becomes equipment-dependent on production-scale machines. One observed failure mode in twin-shell blenders is dead-spot accumulation at the intensifier bar; the corrective action is to operate at 25 rpm for 20 minutes after the final lubricant addition rather than using an extended pre-blend cycle.

Dry powder for in-house veterinary compounding is the most conservative format when the prescriber must vary the dose across a wide body weight range. The API is dispensed as a triturate at 0.2–5.0% w/w with lactose monohydrate 80M as the diluent. Geometric dilution is mandatory: the initial 1:1 API-lactose trituration is passed through a 150 µm stainless steel sieve, then the 1:2 and 1:4 dilutions are each mixed for 3 minutes in a porcelain mortar or a planetary mixer at 50 rpm. Homogeneity is verified by withdrawing 10 samples from different locations and assaying by a stability-indicating liquid chromatographic method; the acceptance range is 90.0–110.0% label claim with relative standard deviation not more than 5.0%. The powder is filled into low-density polyethylene powder jars with a screw cap and a heat-sealed induction liner. A silica gel desiccant carton is inserted if the ambient relative humidity exceeds 60% RH. Assigned beyond-use date under USP <795> is 180 days for the dry non-aqueous formulation. The powder format is not suitable for aqueous reconstitution on the pharmacy floor unless the final solution is used immediately, because unpreserved liquids carry a beyond-use date of 14 days under refrigerated conditions per USP <795> and lobeline base may precipitate if the vehicle pH is not controlled.

If a Premix Is Requested for Individual Animal Oral Administration

Oral premixes are prepared only as non-sterile dry dilutions for individual animal administration, not as commercial medicated feed articles. The regulatory boundary is material: many jurisdictions do not list lobeline as an authorized feed additive, and a commercial feed premix would require a marketing authorization under Regulation (EU) 2019/4 or applicable national feed legislation. For a single-animal premix, lobeline hydrochloride is diluted at 0.1–1.0% w/w onto a carrier composed of lactose monohydrate 200M and pregelatinized starch 5–10% w/w. Mixing is performed in a 50 kg ribbon blender at 25 rpm for 12–15 minutes after a 1:10 manual pre-blend has been screened through a 500 µm sieve. The product is filled into single-dose sachets or aluminum-laminated pouches. Each sachet is labeled with the quantitative composition, a batch number, and the target animal identity because the product is not intended for group administration. Residual solvent limits follow VICH GL18, and the API must be accompanied by a certificate of analysis showing identity, assay, related substances, residual solvents, and microbial limits. The premix is mixed with a small amount of feed immediately before administration; prolonged storage of medicated feed exceeds the compounding-use condition and may trigger feed-safety obligations. For food-producing species, withdrawal periods cannot be established from this format without residue studies.